• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Myopia Patient Case #1

Opinion
Video

Dr Noha Ekdawi discusses her approach to managing myopia in an 8-year-old child using low-dose atropine and tracks the child’s myopia progression over the course of 5 years.

Noha Ekdawi, MD, FAAP: My name is Noha Ekdawi. I’m a pediatric ophthalmologist at Wheaton Eye Clinic [in Wheaton, Illinois]. I’ve been doing myopia management for the last 10 years, and I’ve picked some cases to discuss today.

Patient case 1: This is an 8-year-old who initially presented to me with a very strong family history of myopia. She is otherwise healthy, no complications, no prematurity. Mom, as you see, is a -8. Dad is even higher, -11, and maternal grandfather had a retinal detachment.

This family was very keen on myopia management. I first saw them in September of 2017, and the child was only -1 and a quarter, but again, the parents were very eager to start myopia management, and so I started, at that time, my dose was 0.01%. I saw them back a little over a year later in November of 2018, and she had progressed quite significantly. She went from -1 to a -2.25, then -1 to -2.5. You see there’s a significant progression here of a 1 diopter in the right eye and a diopter and a quarter in the left eye. At that point, we decided that it was better to increase the dose of atropine, and I increased to 0.025%.

Then we saw her back in May of 2019 and November of 2019, and we had stability. On May 15th, 2020, again, stable, no changes in vision. On May 20, 2021, we see now she’s been on 2 and a half years of atropine, 0.025%, and again, we had a small progression. What to do? In September of 2021 is when I started to recommend MiSight contacts. I referred her for MiSight contacts, but for one reason or another, she returned with a multifocal contact lens. In September, again, a year later, now we have another smaller increase in myopia, and then when I last saw her in May of 2023, which is just earlier this year, she had completely stopped atropine in February without a visit, and she had progressed a little more to a -4 in each eye, and you see that her axial lengths were high at 25.77 mm and 25.62 mm.

This was a definite increase. When we look at this girl from 8 years old to 13 years old, she progressed from -1 and a quarter to a -4. That’s almost a 3-diopter increase in 5 years. She is still better than both parents, but were we successful? That’s the main question here. The key is she’s still not even a -6, so we want to be happy, but she’s only 13, so we’ll have to wait and see and follow how she does.

Transcript is AI generated and edited for clarity and readability.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Video 2 - "Do Dry Eye Diagnostics Change the Management of Dry Eye?"
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Kelsey Roelofs, MD, details collaborative strategies for the management of thyroid eye disease
CIME 2024: Diagnostic tips and treatments for managing Demodex blepharitis
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
© 2024 MJH Life Sciences

All rights reserved.